China's healthcare sector recorded a 1.3% decline over the week, an outcome that coincided with announcements from authorities in both the United States and China signaling closer oversight of licensing agreements. During the same period the Hang Seng Index fell 1.7%.
On a year-to-date basis, the healthcare group has underperformed more sharply, down 8.1% compared with a 1.7% decline in the Hang Seng Index. Yet within the broader sector there were pockets of strength: contract development and manufacturing organizations (CDMOs) and biotechnology companies rose 7.0% and 6.7%, respectively.
Regulatory and market context
Regulators in China have moved to tighten controls over online prescription drug sales. The new rules require that licensed pharmacists lead reviews of artificial intelligence systems used in that context, and that buyers be authenticated by real-name verification processes. Separately, proposals in the U.S. to extend the COINS Act to biotechnology have weakened sentiment in the sector. If the proposed legislation is enacted, it could either ban or require review of U.S. investments in Chinese biotechnology firms, a change that could affect equity transactions, mergers and acquisitions, and deals involving new companies.
Market participants are also watching the ASCO conference, scheduled to run from Friday through June 2, for data and developments that could influence sentiment.
Clinical readouts and corporate transactions
Clinical and commercial progress continued to shape company-level performance. Hengrui reported that HRS-7535, an oral GLP-1 agonist for type 2 diabetes co-developed with Kailera, produced reductions in HbA1c of up to 1.68% at week 32 in a phase III trial conducted in China.
Dealmaking remained active despite regulatory headwinds. Innovent and Pfizer reached a collaboration agreement valued at $10.5 billion, which includes $650 million in upfront payments and milestone payments potentially totaling $9.85 billion. The pact covers 12 oncology programs; eight early-stage assets originating from Innovent are licensed to Pfizer, while four programs are structured as co-development projects.
WuXi Biologics secured a five-year commercial supply arrangement with U.S. biotechnology company Viridan Therapeutics (NASDAQ: VRDN). Under the agreement, WuXi Bio will serve as a major non-exclusive supplier for veligrotug, an IF-1R antibody intended to treat thyroid eye disease.
Capacity and regulatory filings
Pharmaron committed approximately 3.0 billion yuan to build a facility in Shaoxing aimed at expanding capacity for intermediates and active pharmaceutical ingredients. Meanwhile, Medtide's subsidiary Zhongtai Biochem received an FDA acknowledgment letter related to a drug master file (DMF) registration for the tirzepatide active pharmaceutical ingredient.
The mix of regulatory tightening and sustained commercial and clinical progress has created a bifurcated market: headline regulatory developments have pressured sentiment broadly, while company-specific clinical data, strategic collaborations, and supply contracts have supported selective gains within the sector.